glp-1 drugs for parkinson's disease does not slow progression in phase 3 study Ozempic and other GLP-1 drugs

The episode explores the science, clinical applications, and real-world considerations surrounding todays most discussed peptide therapies

Front Behav Neurosci 15:786855

Neuronutrition interventions could help clinicians to provide personalized non-pharmocogical recommendations for patients with FM based on their symptoms and mechanisms of nutrient action

We generated GS via photolytic homolysis of the S-N bond of S -nitrosoglutathione (GSNO) 30

3a), and renders the synthesis of cysteine dependent on the activity of one-carbon metabolism (methionine and folate cycles)

From deep visceral fat loss to improved sleep, cognitive sharpness, and lean muscle preservation, the potential is huge